"Dudes, to get to a stock price of $5 we need annual earnings of over $60,000,000."

Based on what set of valuation standards?  Biotechs vs retail vs tech and so on....plenty of companies are trading at multiples not supported by revenues or profits.

EDIG has gone from .07 to 4, back to 1, then onto 24 and back to under a dime with no rational connection to actual revenues.

If the market DM targets is understood by investors, which it is imo, and they believe there are reasonable expectation for success, then the risk-reward play enters....whether or not EDIG books $60 million in revs 3 years from now will not necessarily effect the share price in the short term, as DM reveals its game plan.

I would expect the market to value the potential long before you see the resultant revenues booked, imo.